Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.42 |
| ▸ | KDR | P35968 | 7/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.41 |
| ▸ | LCK | P06239 | 4/20 | 0.41 |
| ▸ | FYN | P06241 | 4/20 | 0.41 |
| ▸ | LYN | P07948 | 4/20 | 0.41 |
| ▸ | MARK3 | P27448 | 4/20 | 0.41 |
| ▸ | FLT3 | P36888 | 4/20 | 0.41 |
| ▸ | BLK | P51451 | 4/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.41 |
| ▸ | STK3 | Q13188 | 4/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.41 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.41 |
| ▸ | MARK2 | Q7KZI7 | 4/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15221929 | 0.89 | IMPDH2 (0.45) | RIPK1KDRAURKBNTRK1LCK | |
| SCHEMBL275031 | 0.88 | RIPK1 (0.56) | RIPK1KDRAURKBNTRK1LCK | |
| SCHEMBL15221841 | 0.84 | KDR (0.49) | KDRAURKBNTRK1LCKFYN | |
| SCHEMBL3619844 | 0.84 | MEN1 (0.56) | RIPK1KDRAURKBNTRK1LCK | |
| SCHEMBL15221930 | 0.83 | KDR (0.47) | RIPK1KDRAURKBNTRK1LCK | |
| SCHEMBL3620695 | 0.82 | RIPK1 (0.55) | RIPK1KDRAURKBNTRK1LCK | |
| SCHEMBL3612618 | 0.82 | NPC1 (0.41) | KDRAURKBNTRK1LCKFYN | |
| SCHEMBL15221928 | 0.81 | KDR (0.53) | KDRAURKBLCKFYNLYN | |
| SCHEMBL3619746 | 0.81 | FLT1 (0.55) | RIPK1KDRAURKBNTRK1LCK | |
| SCHEMBL3612539 | 0.81 | RIPK1 (0.53) | RIPK1KDRAURKBNTRK1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133995-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | BAYER HEALTHCARE LLV (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | CDK4, FLT4, CDKL4 | RIPK1 2129/4885KDR 27/4885AURKB 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.